Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNostrum Oil&gas Regulatory News (NOG)

Share Price Information for Nostrum Oil&gas (NOG)

Share Price is delayed by 15 minutes
Get Live Data
3.50    0.00 (0.00%)
Bid:
3.00
Ask:
4.00
Spread: 1.00 (33.333%)
Market Cap: £5.77m
NOG Live PriceLast checked at - London Stock Exchange

Intraday Nostrum Oil&gas Share Chart

Form 8.3 - Nostrum Oil & Gas plc

8 Jan 2020 14:36

Aberforth Partners LLP - Form 8.3 - Nostrum Oil & Gas plc

Aberforth Partners LLP - Form 8.3 - Nostrum Oil & Gas plc

PR Newswire

London, January 8

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON

WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Aberforth Partners LLP, on behalf of discretionary clients.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Nostrum Oil & Gas plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 07/01/2020
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”YES / NO / N/A NO If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares
InterestsShort positions
Number%Number%
(1) Relevant securities owned and/or controlled: 19,190,963 10.20% 0 0.0
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL: 19,190,963 10.20% 0 0.0

Aberforth Partners LLP does not have discretion regarding voting decisions in respect of 5,965,977 shares included in the total disclosed above. This total includes 5,965,977 shares held by The Wellcome Trust, who retain voting control over their shareholding. No other client, who falls into this category, holds more than 1% of the relevant security.

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:N/A
Details, including nature of the rights concerned and relevant percentages:N/A

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
Ordinary Shares Purchase 40,000  17.4877p

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
N/A

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
N/A

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
N/A

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure: 08 January 2020
Contact name:Michael Campbell, for Aberforth Partners LLP
Telephone number:0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
1st Jun 20267:00 amRNSPublication of Annual Report and Notice of AGM
26th May 20267:09 amRNS1st Quarter Results
14th May 202610:59 amRNSUpdate re Kazakhstan withholding tax disputes
7th May 20265:11 pmRNSBoard Change
30th Apr 20267:00 amRNSOperational Update for Q1 ended 31 March 2026
29th Apr 20267:00 amRNSFull Year Results
30th Mar 202611:38 amRNSProposed Transaction
17th Feb 202611:51 amRNSFurther update on Kazakhstan withholding tax
9th Feb 20269:17 amRNS-RUpdate re Kazakhstan withholding tax disputes
9th Feb 20267:00 amRNSBoard Committee Changes
3rd Feb 20269:38 amRNS-RUpdate on Kazakhstan withholding tax disputes
30th Jan 20267:00 amRNSOperational Update for Q4 and FY2025
26th Jan 202612:18 pmRNSBoard Change
2nd Jan 20268:30 amRNSNotice of delayed interest payments on notes
19th Dec 20255:02 pmRNSFurther statement in relation to AGM vote
19th Dec 20255:02 pmRNSFurther statement in relation to AGM vote
25th Nov 20257:00 amRNSFinancial results for Q3 and 9M 2025
21st Nov 20257:00 amRNSAppointment of NED and Board Committee Changes
31st Oct 202511:27 amRNSBoard Committee Change
31st Oct 20257:00 amRNSOperational Update for 3Q and 9M 2025
24th Oct 20257:00 amRNSAppointment of a NED and Board Committee Changes
17th Oct 20257:00 amRNSAppointment of Nikolay Ivin as Chairman
6th Oct 202510:57 amRNSConsent Solicitation Results
24th Sep 202510:02 amRNSConsent Solicitation
19th Sep 202512:38 pmRNSNew CFO
16th Sep 20254:35 pmRNSConsent solicitation results at early consent date
16th Sep 20253:40 pmRNSMaterial related party transaction and new COO
2nd Sep 20255:23 pmRNSConsent solicitation re payment delay on notes
29th Aug 20257:00 amRNSFinancial results for Q2 and 6M ended 30 June 2025
31st Jul 20257:00 amRNSOperational Update for Q2 and H1 2025
30th Jul 20259:19 amRNSUpdate: delayed interest payments,proposed actions
22nd Jul 20253:33 pmRNSUpdate: delayed interest payments,proposed actions
15th Jul 20255:37 pmRNSAppointment of CEO and a Non-Executive Director
10th Jul 202511:38 amRNSNotification of delayed interest payments
30th Jun 20251:48 pmRNSStakeholder discussions and Board changes
30th Jun 202512:18 pmRNSResult of AGM
6th Jun 202511:43 amRNSPublication of Annual Report and Notice of AGM
20th May 20257:00 amRNS1st Quarter Results
30th Apr 20257:00 amRNSOperational Update for Q1 2025
25th Apr 20253:25 pmRNS2024 Report on Payments to Governments
23rd Apr 20257:00 amRNSFull Year Results
10th Apr 20253:20 pmRNSTR-1: Notification of major holdings
7th Apr 20258:41 amRNSShares Cancellation, Change in Total Voting Rights
4th Apr 20257:00 amRNSApproval of Stepnoy Leopard Field Development Plan
21st Mar 20257:00 amRNSProcessing Agreement extension with Ural Oil & Gas
6th Feb 202511:52 amRNSHolding(s) in Company
31st Jan 20257:00 amRNSOperational Update for Q4 and FY2024
12th Dec 202412:01 pmRNSHolding(s) in Company
2nd Dec 20244:17 pmRNSPurchase and Cancellation of Deferred Shares
19th Nov 20247:00 amRNSFinancial Results for Q3 and 9M 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.